ライフサイエンスコーパス: PIH

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 PIH's experience in Sierra Leone is one of multiple part

2 However, after 59Fe-PIH uptake 59Fe release from S and R cells was similar.

3 We found that both 59Fe-Tf and 59Fe-PIH uptake were decreased in R cells.

4 The uptake of 59Fe-Tf but not 59Fe-PIH could be blocked by an anti-TfR monoclonal antibody.

5 lex sensitivity (BRS) was impaired in NP and PIH women relative to NN.

6 rtum in women with normal pregnancy (NP) and PIH and in normotensive nonpregnant (NN) women.

7 g, inverse relation between birth weight and PIH risk (p for trend < 0.0001).

8 Lessons learned by PIH and its partners in Sierra Leone can contribute to t

9 d contrast to the cellular uptake of (1)(4)C-PIH and (1)(4)C-Bp4eT, which were linear as a function o

10 C-pyridoxal isonicotinoyl hydrazone ((1)(4)C-PIH) and the thiosemicarbazone ((1)(4)C-2-benzoylpyridin

11 cium intake, and women at risk of developing PIH, may benefit from consuming additional dietary calci

12 onversely, the PIH1D1 phospho-binding domain PIH-N is required for association with MRE11 phosphoryla

13 cribe how, in the aftermath of the epidemic, PIH is partnering with the public sector to strengthen t

14 en the risk for laser-induced or exacerbated PIH.

15 en the risk for laser-induced or exacerbated PIH.

16 eight showed a U-shaped relation to risk for PIH, with the highest risks associated with very low and

17 ncluded studies involved laser treatment for PIH with the degree of pigmentation as a measure of outc

18 finger-probe with pulse inversion harmonic (PIH) capability.

19 ow the international NGO Partners In Health (PIH) partnered with the Government of Sierra Leone and W

20 rs of the pyridoxal isonicotinoyl hydrazone (PIH) class can restrict the growth of clinically signifi

21 and 59Fe-pyridoxal isonicotinoyl hydrazone (PIH) to determine whether the decrease in iron uptake by

22 tion for postinflammatory hyperpigmentation (PIH) but can pose a clinical dilemma given the risk for

23 tion for postinflammatory hyperpigmentation (PIH) but can pose a clinical dilemma given the risk for

24 tic drive in pregnancy-induced hypertension (PIH) and preeclampsia (PE).

25 treatment of pregnancy-induced hypertension (PIH) is reviewed.

26 ter risk for pregnancy-induced hypertension (PIH), a disorder associated with insulin resistance and

27 al of pharmacologically induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist

28 similar age and body weight but less than in PIH women (P<0.001) (146+/-23.5 impulses/100 beats).

29 articularly fetal growth, in the etiology of PIH.

30 ween dietary calcium intake and incidence of PIH.

31 Screening a library of PIH derivatives revealed that one compound, namely, 2-py

32 cise factors involved in the pathogenesis of PIH are unclear, but several alterations in calcium meta

33 the 22,955 remaining women with no record of PIH.

34 lasers may be beneficial in the treatment of PIH.

35 lasers may be beneficial in the treatment of PIH.

36 ce for the use of lasers in the treatment of PIH.

37 ce for the use of lasers in the treatment of PIH.

38 determine the benefit of laser treatment of PIH.

39 tudies showed no improvement or worsening of PIH after laser treatment.

40 These results suggest that PIH induced by neurotensin analogs represented by ABS-20

41 The PIH therapy using ABS-201 improves recovery of sensorimo

42 CE-IOUS in the PIH mode was performed in a standardized protocol (low M

43 oke are reduced by approximately 30-40% when PIH therapy is initiated either immediately after stroke

44 Cases were 2,180 women diagnosed with PIH.

45 Twenty-one women with NP, 18 women with PIH, and 21 NN women had muscle sympathetic nerve activi

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。